影响子宫肌瘤栓塞治疗的因素

目的观察子宫动脉栓塞术(UAE)对子宫肌瘤的治疗效果,并分析影响疗效的因素。方法46例症状性子宫肌瘤患者经超选择性插管双侧子宫动脉内注入PVA微粒栓塞治疗,术后6、9个月随访复查,观察临床症状改善,肌瘤体积变化情况,并对临床上治疗效果与多种不同的影响因素进行分析。结果UAE术后临床症状改善,尤其以子宫出血症状改善最为明显,栓塞后6个月肌瘤体积平均缩小45.6%,9个月肌瘤体积平均缩小58.4%。盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等因素影响子宫肌瘤栓塞后的疗效。结论双侧子宫动脉栓塞治疗子宫肌瘤是一种安全、有效的方法,其疗效与盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等多种因素有关。     

UAE治疗不同类型症状性子宫肌瘤中期疗效及安全性研究

目的 探讨子宫动脉栓塞术(UAE)治疗不同类型症状性子宫肌瘤中期临床疗效和安全性。方法 回顾性分析行UAE治疗的33例患者的临床资料,分析患者术后月经评分、临床有效率、不良反应及并发症,比较术前和术后6个月肌瘤体积缩小率、月经量减少率,比较术前和术后6个月不同类型症状性子宫肌瘤的疗效。结果 UAE治疗子宫肌瘤疗效确切,术前和术后6个月肌瘤体积缩小率、月经量减少率差异均有统计学意义(P<0.05)。对不同类型子宫肌瘤治疗效果无明显差异(P>0.05)。术后无严重不良反应及并发症发生。结论 UAE治疗症状性子宫肌瘤安全有效,对不同类型子宫肌瘤疗效无差异,在保留子宫的同时能显著缓解患者临床症状。     

高压明胶海绵微粒动脉内栓塞治疗子宫肌瘤的临床观察

目的:评价高压明胶海绵微粒作为栓塞剂动脉内栓塞治疗症状性子宫肌瘤的安全性和有效性。方法:用高压明胶海绵微粒动脉内栓塞治疗173例子宫肌瘤患者,随访3~36个月,平均15.7个月,观察临床疗效、肌瘤和子宫体积的变化。结果:术后4个月总的症状改善率98.84%(171/173),160例(92.49%)患者术后月经完全恢复正常;5例(2.89%)患者出现术后永久闭经;痛经与直肠和膀胱压迫等症状均完全消失。术后6个月子宫体积平均缩小49.35%,肌瘤平均缩小59.78%。结论:采用高压明胶海绵微粒作为栓塞剂栓塞子宫动脉治疗症状性子宫肌瘤是一种经济、安全、有效的新方法。     

超声在子宫肌瘤的子宫动脉栓塞术疗效评价中的价值

目的:探讨超声在子宫动脉栓塞术治疗子宫肌瘤术后疗效随访中的应用价值。材料和方法:58例子宫肌瘤患者分别在栓塞术前1周、术后1个月、6个月、12个月运用超声观察子宫大小形态、肌瘤大小形态和血流动力学的改变。结果:术后1个月子宫体积平均缩小44.24%,肌瘤体积平均缩小43.74%;术后6个月子宫体积平均缩小62.72%,肌瘤体积平均缩小61.25%;术后1年子宫体积平均缩小72.17%,肌瘤体积平均缩小70.18%。其中以单发肌瘤、内膜肌瘤患者疗效明显,肌瘤的血供较术前明显减少。结论:超声在评价子宫动脉栓塞术治疗子宫肌瘤术后疗效中有重要价值。     

子宫肌瘤的介入治疗

目的　评价子宫动脉栓塞术治疗子宫肌瘤的疗效。方法　对 182例子宫肌瘤患者进行超选择性子宫动脉栓塞术。结果　栓塞双侧子宫动脉 173例 ,单侧 9例。 168例完整随访者术后 6个月子宫体积平均缩小 42 % ,16例肌瘤消失 ,15 2例肌瘤体积平均缩小 67%。临床症状明显改善。主要副作用为下腹部疼痛 ( 13 5 /182 )。结论　子宫动脉栓塞术是治疗子宫肌瘤的良好方法。     

子宫动脉栓塞治疗子宫肌瘤的生命质量观察

目的 探讨子宫动脉栓塞前后子宫肌瘤患者的生命质量变化.方法 对2003年1月-2005年3月我院收治118例行子宫动脉栓塞术患者,应用子宫肌瘤症状和生命质量(UFS-QOL)调查表评价其术前及术后生命质量的变化,并对患者进行满意度调查.同时观察子宫及肌瘤大小变化.结果 术后6个月肌瘤及子宫体积平均分别缩小49.6%和45.2%.栓塞术后患者临床症状明显好转,生命质量各因子评分均较术前明显提高,差异均有统计学意义(P＜0.001),65%患者临床症状明显改善,接近80%患者肯定或很可能再次选择UAE治疗子宫肌瘤.结论 行UAE治疗子宫肌瘤,可明显提高患者的生命质量,有较高的满意度.     

选择性子宫动脉栓塞治疗子宫腺肌病的临床研究

目的 :研究选择性子宫动脉栓塞 (UAE)治疗子宫腺肌病的临床效果。方法 :对 2 5例经临床、超声或MRI诊断为子宫腺肌病的患者行UAE。采用Seldinger技术经股动脉穿刺 ,将导管选择性插入双侧子宫动脉 ,经导管注入真丝线段和明胶海绵微粒栓塞 ,阻断异位内膜病灶血供。术后观察月经量、痛经程度及子宫、病灶体积等变化。结果 :所有病例随访 3～ 12个月 (平均 8个月 ) ,临床症状缓解率 96%。月经量均恢复正常。 2 0例患者术后痛经完全消失 ,4例明显缓解 ,1例复发 ;栓塞后 6个月 ,子宫体积平均缩小 48.4% ,14个腺肌瘤体积平均缩小 47.1% ;超声检查子宫肌层及病灶内血流信号明显减少。无严重并发症发生。结论 :UAE治疗子宫腺肌病是一种安全、近期疗效显著的方法 ,远期疗效尚需进一步观察。     

超选择子宫动脉栓塞术治疗子宫肌瘤疗效及并发症分析

目的：研究超选择子宫动脉栓塞术（UAE）对子宫肌瘤的临床疗效。方法：我院于1999年8月－2001年6月对405例子宫肌瘤患者进行双侧子宫动脉栓塞并对其进行随访分析疗效。结果：插管的成功率为99．8％，随访3－12个月。B超示术后3个月肌瘤体积平均缩小40％－60％，6个月后子宫肌瘤体积平均缩小50％－70％，其中22个肌瘤消失。96％的患者症状消失或改善，并发症发生率1％。结论：子宫肌瘤的介入治疗是一种创伤小，恢复快，疗效肯定的方法。     

子宫动脉栓塞术治疗子宫肌瘤的临床研究

目的评价子宫动脉栓塞术（UAE）治疗子宫肌瘤的临床效果。方法对49例经临床、超声或MRI诊断为子宫肌瘤的患者行UAE，采用Seldinger技术经股动脉穿刺，将导管选择性插入双侧子宫动脉，经导管注入聚乙稀醇颗粒（PVA）、海藻酸钠微球（KMG）或明胶海绵微粒栓塞，阻断肌瘤供血动脉。术后定期观察月经量、一般症状、子宫与病灶体积变化。结果术后所有患者临床症状均有明显改善或消失，月经恢复正常，子宫肌瘤均有不同程度的缩小，无严重并发症发生。结论动脉栓塞治疗子宫肌瘤是一种微创性的治疗手段，可使肌瘤进行性缩小，临床症状改善，是子宫肌瘤临床治疗的又一种选择。     

动脉栓塞术治疗子宫肌瘤远期疗效的观察

目的:探讨子宫动脉栓塞术(UAE)治疗子宫肌瘤的远期疗效。方法:37例子宫肌瘤患者行子宫动脉栓塞术,平均随访3年。结果:子宫肌瘤血供丰富,均为双侧子宫动脉供血,一侧为主,4例卵巢动脉参与供血,供血动脉粗大、迂曲,在瘤体的周围及内部形成血管网、团,瘤体染色明显。术后随访B超显示肌瘤缩小明显、临床症状改善,有效率达100%,无1例复发。结论:子宫动脉栓塞术治疗于宫肌瘤是一种高效、微创、安全且经济的方法,远期疗效好,值得临床应用推广。     

经导管子宫动脉栓塞治疗症状性子宫平滑肌瘤的初步经验

目的 评价经导管子宫动脉栓塞（ＵＡＥ）对症状性子宫平滑肌瘤（ＵＦ）的疗效并探讨治疗技术。方法 １０例患者主要症状包括阴道出血（月经过多）,盆腔压迫症状（尿频）,盆区疼痛。ＵＦ的诊断经影像学检查和专科医师检查确定,并排除与症状有关的其它妇科疾病。１０例患者行１１例次子宫动脉栓塞,其中双侧者１０例次,单侧者１例次。栓塞剂为ＰＶＡ微球。结果 栓塞技术成功率为１００％,无严重并发症。随访９例,术后症状有明     

Limited uterine artery embolization with tris-acryl gelatin microspheres for uterine fibroids

PURPOSE: To evaluate the midterm results of limited embolization of the uterine arteries in the management of symptomatic uterine fibroids and to evaluate the efficacy and safety of limited uterine artery embolization (UAE) with use of calibrated tris-acryl gelatin microspheres in the management of symptomatic uterine fibroids. MATERIALS AND METHODS: Twenty women (mean age, 43 years) with symptomatic uterine fibroids underwent bilateral embolization of the uterine arteries with use of calibrated microspheres. Devascularization of the fibroids was achieved and the main uterine artery was left patent in all women. Embolization was offered as an alternative to surgery in all women who had been treated unsuccessfully with medical therapy. RESULTS: All procedures were technically successful. Microspheres 700-900 micro m in diameter were used in 14 women (70%). After a mean follow-up duration of 30.2 months (range, 24-48 mo), all women reported improvement in their symptoms, with 85% reporting complete resolution of menorrhagia at the most recent follow-up. One woman with multiple fibroids required a second embolization procedure because of persisting symptoms at 6 months. She is currently symptom-free after 48 months. In two women with submucosal fibroids, expulsion of necrotic fibroids occurred 2 and 7 months after the procedure, respectively. All women resumed normal menstruation after the procedure. One woman had a successful full-term pregnancy after embolization. CONCLUSION: Early experience with UAE with use of calibrated tris-acryl gelatin microspheres indicates that it is safe and efficacious in controlling menorrhagia.     

子宫肌瘤介入治疗前后CT动态扫描血供变化的研究

目的 研究子宫肌瘤介入治疗前后子宫与肌瘤血供变化。方法 16例单发症状性子宫肌瘤患者接受子宫动脉栓塞治疗，术前、术后7d及术后3个月选择同层面进行CT动态增强扫描，测量正常子宫及肌瘤的CT值，进行栓塞前后对比分析。结果 16例患者每次均顺利完成CT动态增强扫描，术前、术后7d及术后3个月正常子宫组织动态增强曲线及CT值无明显改变，而肌瘤动态增强曲线及CT值有明显改变，肌瘤栓塞后处于持续性缺血状态。结论 子宫动脉栓塞术治疗子宫肌瘤是一种安全，有效的新疗法，子宫动脉栓塞后非肌瘤子宫组织血供不受影响。     

Uterine artery embolization treatment of uterine fibroids: effect on ovarian function in younger women

PURPOSE: To evaluate how uterine artery embolization (UAE) treatment for uterine fibroids (UF) affects ovarian function in young Middle Eastern women. MATERIALS AND METHODS: In this prospective study, 32 patients (mean age, 34 y; range, 26-45 y) underwent UAE treatment of symptomatic fibroids. Serum follicle-stimulating hormone (FSH) levels were measured before and after the embolization treatment. Preprocedural levels were determined on the second day of the menstrual cycle. Postprocedural levels were measured 3 months and 6 months after embolization. A detailed history of menstrual cycles was obtained before and after UAE. RESULTS: Thirty premenopausal patients had normal menses before UAE. Mean FSH levels before and 3 months after UAE were 6.83 IU/L +/- 1.8 and 6.99 IU/L +/- 1.67, respectively (P =.66). Normal menstruation resumed 2-3 months after the procedure. In two perimenopausal women, who had irregular menses and decreased ovarian reserve, mean FSH levels increased transiently from 22 and 30 IU/L to 40 and 48 IU/L, respectively, 3 months after UAE; they developed transient amenorrhea. CONCLUSION: In this study, UAE had no clinically relevant adverse effects on normally functioning ovaries and could be used safely in the treatment of symptomatic fibroids in premenopausal women. Larger studies are required for further support of this observation.     

子宫动脉栓塞术治疗子宫肌瘤的疗效评价

目的：探讨子宫动脉栓塞术治疗子宫肌瘤的疗效。方法自2010年1月-2013年8月,我科共对19例子宫肌瘤患者进行了子宫动脉栓塞术,年龄35-52岁,平均年龄42岁。症状包括经期延长、月经量增多、尿频等。采用改良Seldinger技术穿刺股动脉后,分别行两侧子宫动脉栓塞。术后随访6个月,观察治疗效果及并发症。结果19例患者均成功行双侧子宫动脉栓塞,技术成功率100％,所有患者临床症状均得到改善,其中2例因子宫肌瘤导致不孕的患者,术后怀孕。术后大多数患者出现下腹痛、发热、阴道不规则流血等症状,无子宫坏死、子宫积脓等严重并发症发生。结论介入治疗对子宫肌瘤患者是一种安全、有效的方法。     

平阳霉素碘油乳剂子宫动脉栓塞治疗症状性子宫肌瘤

目的 评价平阳霉素碘油乳剂（Ｐｉｎｙａｎｇｍｙｃｉｎ ｌｉｐｉｏｄｏｌ ｅｍｕｌｓｉｏｎ,ＰＬＥ）子宫动脉灌注对症状性子宫肌瘤的疗效和副作用。方法 对２５例症状性子宫肌瘤患者进行选择性子宫动脉ＰＬＥ灌注,随访３～１８个月,平均６个月,观察术后症状缓解情况和子宫缩小程度。结果 除２例仅完成单侧操作外,其余均治疗成功。子宫肌瘤的动脉造影表现为子宫动脉明显增粗,分支数量增多、纡曲。子宫体增大,染色明显并     

Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results

PURPOSE: To evaluate reduction in fibroid volume, the effect on clinical symptoms, adverse events and complications after percutaneous uterine artery embolization (UAE) as primary invasive treatment for symptomatic uterine fibroids. MATERIAL AND METHODS: Sixty-two patients entered the study. Indications for treatment were fibroid-induced menorrhagia, bulk symptoms, pain, and/or large fibroid size. The first 50 patients were evaluated by clinical examination and ultrasonography with measurement of fibroid volume before treament and 1, 6 and 12 months after UAE. The remaining 12 patients were followed 3 and 12 months after treatment. Embolization with microparticles was performed percutaneously in local analgesia by selective catheterization of both uterine arteries. RESULTS: A primary technical success with bilateral UAE was achieved in 60/62 (97%) of the patients. They were treated for postprocedural pain lasting up to 24 h. In 30 of the 62 patients with 6 months follow-up, the mean fibroid volume was reduced 68% 6 months after treatment. Twenty-nine (96%) of the patients experienced reduced bleeding, 21 (70%) reduced pain, and 18 (61%) reduced bulk symptoms at follow-up. CONCLUSION: UAE is a method with a high technical success rate. The treatment has good effect on fibroid volume reduction and clinical symptoms. Severe post-procedural pain occurs generally in successful bilateral embolizations, but complications and adverse events are otherwise few and minor. UAE represents a promising new method for treating uterine fibroid-related symptoms.     

Mid-term Clinical Results and Patient Satisfaction After Uterine Artery Embolization in Women with Symptomatic Uterine Fibroids

Purpose To evaluate the mid-term clinical results and patient satisfaction following uterine artery embolization (UAE) in women with symptomatic fibroids. Methods Between August 1998 and December 2002, 135 patients had UAE for symptomatic uterine fibroids. All patients were asked to fill in a questionnaire. Questions were aimed at changes in bleeding, pain, and bulk-related symptoms. Symptoms after UAE were scored as disappeared, improved, unchanged or worsened. Adverse events were noted, such as vaginal dryness and discharge, menopausal complaints or fibroid expulsion. Patient satisfaction after UAE was assessed. Patient satisfaction of women embolized with polyvinyl alcohol (PVA) particles was compared with satisfaction of women embolized with calibrated microspheres. Results The questionnaire was returned by 110 of 135 women (81%) at a median time interval of 14 months following UAE. In 10 women additional embolization or hysterectomy had been performed. Of the 110 responders, 86 (78%) were satisfied with the result of UAE. The proportion of satisfied women was higher in the group embolized with calibrated microspheres than in women embolized with PVA, although this difference was not statistically significant (p = 0.053). Conclusion UAE in women with symptomatic uterine fibroids leads to improvement of symptoms and patient satisfaction is good in the vast majority after a median follow-up period of 14 months.